Talem Therapeutics is a wholly owned subsidiary of ImmunoPrecise Antibodies and is focused on the
discovery and development of next-generation, fully human, monoclonal, therapeutic antibodies targeting emerging, infectious diseases, neurology, immuno-oncology, inflammation, and rare/specialty diseases. Using the proprietary
antibody discovery platforms and innovative technologies housed at ImmunoPrecise Antibodies, Talem aims to accelerate novel, therapeutic antibody treatments to the clinic through strategic alliances and partners.
The demand for safe, therapeutic, monoclonal antibody candidates with more complex target product profiles is driving a need for more robust discoveries. Talem was founded to expedite the high-powered discovery and development of custom therapeutics produced as both internal assets as well as in response to partnership requests with large pharma.
Talem has been actively involved in COVID-19 research since January 2020. Monoclonal antibodies were derived from several animal species, including transgenic OmniRat® rodents, rabbits, llama, and human, to access a broad epitope coverage. We exploit multiple antibody formats, valencies, and sizes to select antibodies against multiple/rare epitopes. Our multinational teams in North America and Europe have developed a rich SARS-CoV-2 antibody portfolio with deep epitope and functional diversity.
Visit talemtherapeutics.com/polytope for more information.
Partner with Talem Therapeutics
We partner to discover your therapeutic antibody. By collaborating with us, we offer interested partners the
use of our proprietary technologies to jointly discover and develop therapeutic antibodies against any target.
We involve you in the discovery process and provide lead candidates in a short amount of time.